Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide  by Sweeney, Elizabeth A et al.
Inhibition of sphingolipid induced apoptosis by caspase inhibitors
indicates that sphingosine acts in an earlier part of the apoptotic pathway
than ceramide
Elizabeth A. Sweeneya;*, Jin-ichi Inokuchib, Yasuyuki Igarashia
aFred Hutchinson Cancer Research Center, 1124 Columbia St., M621, Seattle, WA 98104-2092, USA
bSeikagaku Corporation, Tokyo Research Institute, Tokyo, Japan
Received 26 January 1998; revised version received 14 February 1998
Abstract Caspases are specific proteases involved in apoptosis,
and their inhibition by specific peptide inhibitors can inhibit
apoptosis. With these inhibitors we examined the relationship of
caspases and sphingolipids involved in the induction of apoptosis
of human leukemic HL60 cells. We have previously shown that
sphingosine (Sph) and its methylated derivative dimethylsphin-
gosine (DMS) effectively induce apoptosis in HL60 cells. Using
these lipids as well as ceramide analogues we found both
similarities and differences in the caspase involvement in
apoptosis induced by the two distinct lipid types. The wide-
spectrum caspase inhibitor Z-VAD-FMK and Z-DEVD-FMK,
an inhibitor of the downstream caspases 3 (CPP32, Yama) and 7,
both inhibited apoptosis induced by all the lipids tested. Z-AAD-
FMK which inhibits the serine protease Granzyme B, inhibited
Sph/DMS induced apoptosis, but little or no effect on ceramide
induced apoptosis. Granzyme B shares a substrate sequence
preference with upstream caspases capable of activating
themselves and other caspases downstream. Z-IETD-FMK,
which inhibits caspase 8/FLICE also inhibited Sph/DMS induced
apoptosis with no inhibition of apoptosis induced by either
ceramide. Together, these data indicate that Sph/DMS act
independently from ceramide in the apoptosis pathway and
further suggest that Sph/DMS act earlier in the pathway than
ceramide and are involved upstream of even the early proteases,
whereas the point of action for ceramide is downstream of the
early proteases but upstream from the late caspases.
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1. Introduction
The past few years have seen an explosion of information
regarding the demise of cells by a speci¢c set of self-pro-
grammed events termed apoptosis that we are now just begin-
ning to understand. Apoptosis involves a distinct set of mor-
phological and biochemical changes, including nuclear
condensation, DNA fragmentation, and membrane blebbing,
culminating in cell death and compact packaging of the cel-
lular debris into apoptotic bodies [1]. One set of players found
to be important in many steps of apoptosis is a group of
enzymes known as cysteine-directed asparagine proteases (cas-
pases). The ¢rst such protease identi¢ed as being involved in
apoptosis was the product of the ced-3 gene in the nematode
C. elegans, followed by its mammalian homologue interleukin
1 converting enzyme (ICE). Since then, ten mammalian ho-
mologues of ICE have been identi¢ed and designated as cas-
pases 1^10 [2,3].
Recent discoveries have greatly increased our understanding
of this family of enzymes and their preferred substrates. Cas-
pases, which are normally present as zymogens and cleaved to
form active heterodimers, can be divided into three groups
based on preference for tetrapeptide sequences with the requi-
site asparagine in the ¢rst position (and a bias towards a
glutamine in the third) [4,5]. Group I includes caspases 1
(ICE), 4 and 5, preferring the substrate sequence WEHD.
Group II which includes caspases 3 (CPP32/Yama) and 7,
must have asparagine in the 4th as well as the 1st position
(DEXD). Finally, Group III caspases, which include caspases
8 (FLICE) and 6 (Mch 2) are more tolerant of various amino
acids in position 4, but they prefer those with large aliphatic
side chains (XEH/TD). Interestingly, this sequence speci¢city
is shared by the serine protease Granzyme B (GraB). Further-
more, the optimal recognition sequences for Group III cas-
pases (and GraB) are similar to cleavage sites within their
own, or other, caspase prodomains, implicating them in au-
tocatalytic and initial activation of an enzyme cascade [4,5].
Based on the known sequence preferences, tetrapeptide inhib-
itors have been synthesized and are now available commer-
cially.
Apoptosis can be initiated extracellularly, as in receptor
ligand binding, or triggered by internal factors. Short-chain
ceramide analogues have been reported to induce apoptosis in
hematopoietic cell lines such as HL60 [6]. We and others have
recently shown that exogenously added sphingosine (Sph) and
its dimethylated derivative dimethylsphingosine (DMS) can
induce apoptosis in a number of cell lines including HL60
[7^10] and myocytes [11,12]. Evidence suggests that these
two types of lipids work di¡erently within the apoptotic path-
way [13^15]. Still, the precise mechanisms involved in the in-
duction of apoptosis by these sphingolipids are unknown [16].
In the present study we further investigate these mechanisms
using tetrapeptide inhibitors to examine the relationship of
caspases and sphingolipid induced apoptosis. We provide evi-
dence here that suggests that Sph and DMS activate the apop-
tosis pathway early, prior to activation of early caspases,
while the ceramide analogues trigger the pathway downstream
from some caspases but upstream from executor caspases.
2. Materials and methods
2.1. Reagents
The protease inhibitors (Table 1) Ac-YVAD-CHO, Z-VAD-FMK,
Z-DEVD-FMK, and Z-AAD-CMK were purchased from Oncogene
Research Products (Cambridge, MA), and Z-IETD-FMK from En-
zyme Systems Products (Livermore, CA). All inhibitors were kept as
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stock solutions of 20 mM in DMSO and added directly to cell cul-
tures. Fumonisin B1 was purchased from Sigma Chemical Co, St.
Louis, MO.
Sph, C2-ceramide, and C6-ceramide were purchased from Sigma
Chemical Co. DMS was prepared as previously described [17].
(1S,2R)-D-erythro-2-(N-Myristoylamino)-1-phenyl-1-propanol
(MAPP) was prepared according to published reports [18].
2.2. Cell culture
HL60 cells were grown in RPMI/HEPES supplemented with so-
dium pyruvate, sodium glutamate, penicillin-streptomycin, and 10%
heat inactivated (30 min, 55‡C) fetal bovine serum (Hyclone, Logan,
Utah). Assays were performed on 2U105 cells/ml in 24-well tissue
culture plates.
For apoptosis studies, cells were pretreated for 1 h with protease
inhibitors. Lipids were diluted in ethanol/water, 50/50, and added to
cells (ethanol concentration was 6 0.01%) for 5.5 h. Cells were har-
vested and stained as previously described [8]. Brie£y, suspension
cultures were centrifuged, washed in Hanks’ salt solution with Mg2
and Ca2, and resuspended in lysis bu¡er (100 mM Na citrate with
0.1% Triton X-100) containing 50 Wg/ml propidium iodide then stored
overnight at 4‡C in the dark. Cells were analyzed using a Becton
Dickinson FACScan (San Jose, CA). Apoptosis was con¢rmed by
DNA fragmentation patterns using agarose gel electrophoresis [8].
3. Results and discussion
3.1. Sphingosine and ceramide induce apoptosis without
interconversion of the lipids
Since sphingosine and ceramide are catabolites of each oth-
er, we tested the e¡ect on apoptosis of blocking their conver-
sion. As we previously reported [8], blocking ceramide syn-
thesis from sphingosine by the addition of the fungal agent
Fumonisin B1 (25 WM) did not inhibit sphingosine from in-
ducing apoptosis (Fig. 1A). Similarly, DMS, which cannot be
metabolized to ceramide, causes apoptosis. This is in keeping
with the ability of DMS to cause apoptosis since DMS cannot
be metabolized to ceramide. Additionally, inhibiting the deg-
radation of C6-ceramide to sphingosine by the ceramidase
inhibitor MAPP (10 WM) did not inhibit C6-ceramide induced
apoptosis (Fig. 1B). These data indicate that Sph/DMS and
ceramide analogues act independently of conversion in induc-
ing apoptosis.
3.2. Inhibition of sphingolipid induced apoptosis by inhibitors
of execution phase caspases
The irreversible inhibitor Z-VAD-FMK inhibits a wide
spectrum of caspases including the later caspases 3 and 7,
and, to a lesser extent 1 and 4 [19], but also caspase 8 [20]
but does not inhibit Granzyme B activity [21]. Z-VAD-FMK
(25 WM) was found to strongly inhibit apoptosis induced by
all four sphingolipids (Fig. 2). Apoptosis induced by Sph or
DMS was inhibited to baseline levels, and that induced by C2-
or C6-ceramide analogues by 60 and 75% respectively.
To further study the susceptibility of sphingolipid induced
apoptosis to the di¡erent inhibitors, we compared dose curves
of each inhibitor on the induction of apoptosis. In Z-VAD-
FMK pretreated cells, Sph and DMS induced apoptosis was
signi¢cantly inhibited at 5 WM and almost completely inhib-
ited at 10 WM and 25 WM respectively, but C6-ceramide and,
even more so, C2-ceramide induced apoptosis had much less
dramatic decreases, needing 50 WM to inhibit completely (Fig.
3A). This increased sensitivity could be explained by the abil-
ity of Z-VAD to inhibit a broad range of caspases. Apoptosis
triggered early in the pathway by Sph/DMS, as suggested
below, would likely involve more caspases overall, giving Z-
VAD more targets to inhibit, than in apoptosis triggered
downstream by C2-ceramide.
Additionally, we tested sphingolipid induced apoptosis in
the presence of the inhibitor Z-DEVD-FMK which mainly
inhibits Group II caspases, especially the downstream execu-
tion phase caspase 3 and, to a lesser extent 7 [3]. Apoptosis
induced by Sph/DMS and both ceramide analogues was in-
hibited by 75 WM Z-DEVD-FMK, with Sph and DMS in-
duced apoptosis nearly completely inhibited, and that induced
by the ceramides inhibited at 60% for C2-ceramide and 70%
for C6-ceramide (Fig. 2). We also found this inhibition to be
dose dependent. Apoptosis induced by Sph and DMS was
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Table 1
Summary of caspase inhibitors used in this study and their e¡ect on sphingolipid induced apoptosis
Inhibitor
sequence
Target
caspases
Caspase
group
Optimal recognition
sequence
Examples of
substrates
Substrate
sequence
Inhibition of apoptosis
induced bya
Sph DMS C6Cer C2Cer
Ac-YVAD-CHO 1 (ICE), 4 I (W/L)EHD Pro-IL1b YVHD 3 3 3 3
Z-VAD-FMK 1 (ICE), 4 I (W/L)EHD Pro-IL1b YVHD ++++ ++++ +++ +++
3, (CPP32,
Yama), 7
II DEVD PARP DEVD
DNA-dep kinase DEVD
PKC PKCd
8 (FLICE) III LETD Caspase 3
Z-DEVD-FMK 3, (CPP32,
Yama), 7
II DEVD PARP DEVD ++++ ++++ +++ +++
7 DNA-dep kinase DEVD
Z-AAD-CMK Granzyme B III-like IEPD Caspase 3 DEVD +++ +++ + 3
proenzyme
Caspase 7 DEVD
proenzyme
Z-IETD-FMK 8 (MACH,
FLICE)
III LETD Caspase 3 DEVD ++ +++ 3 3
proenzyme
Caspase 8 VETD
proenzyme
aDetermined by £ow cytometry. ++++, completely inhibited; +++, strongly inhibited; ++, moderately inhibited; +, weakly inhibited; 3, not
inhibited.
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inhibited identically at 60^65% inhibition in 20 WM Z-DEVD-
FMK, but that of the ceramides was only 10^15% inhibited.
However, at 75 WM all are inhibited more than 50% (Fig. 3B).
This disparity might re£ect either a di¡erence in the involve-
ment of caspases 3 and 7 in Sph/DMS vs. ceramide induced
apoptosis, or, as with Z-VAD, may represent inhibition of
multiple caspases in Sph/DMS induced apoptosis, as this irre-
versible inhibitor can inhibit other caspases weakly over lon-
ger periods of time [3]. Regardless, the abrogation of sphin-
golipid induced apoptosis by inhibition of these downstream,
executor caspases indicates that all the sphingolipids tested act
upstream from these caspases.
The inhibitor Ac-YVAD-CHO selectively inhibits Group I
caspases, which are now believed to have little involvement in
apoptosis and to be more associated with the pro-in£amma-
tory cytokine processes. Sphingolipid induced apoptosis was
not at all a¡ected by the addition of this inhibitor even in high
concentrations (Table 1). Together, these results con¢rm that
caspases, speci¢cally apoptosis associated caspases, are in-
volved in sphingolipid induced apoptosis, and that these
sphingolipids act upstream of the execution phase caspases.
3.3. Inhibitors of upstream caspases inhibit Sph/DMS induced
but not ceramide induced apoptosis
To examine the roles of sphingolipids in the early apoptosis
pathway, we used inhibitors of GraB and Group III caspases.
GraB is a serine protease involved in NK cell killing which
shares substrate speci¢city with the caspases in Group III,
caspases which include caspase 8 (FLICE) and caspase 6.
Granzyme B and Group III caspases act upstream in the
apoptosis pathway and can cleave the zymogen form of other
caspases (and in some cases their own) [4]. At 50 WM the
GraB inhibitor Z-AAD-FMK inhibited Sph and DMS in-
duced apoptosis by 65 and 70% respectively (Fig. 2). Likewise,
the dose curve of Z-AAD-FMK showed a similar slope for
inhibiting Sph and DMS induced apoptosis, but the Sph in-
duced is more sensitive (Fig. 3C), a di¡erence consistent with
the derivative DMS causing more apoptosis in HL60 cells
than its parent compound Sph, perhaps due to stronger bind-
ing or lack of metabolism of DMS. On the other hand, there
was only a small amount of inhibition in C6-ceramide induced
apoptosis and no inhibition in C2-ceramide induced apoptosis
in the presence of even the highest concentration of Z-AAD-
FMK (Figs. 2 and 3C). The slightly higher amount of apop-
tosis induced by C6-ceramide as opposed to C2-ceramide and
the modest inhibition seen in C6-ceramide induced apoptosis
may re£ect the processing of some C6-ceramide by ceramidase
to Sph. C6-ceramide has been shown to be more susceptible to
cellular metabolism than C2-ceramide ([22], Yang, L., person-
al communication). Metabolism of C6-ceramide may, in fact,
account for the repeated di¡erences in the susceptibility to the
inhibitors between the two analogues.
As there is presumably no GraB in this cell assay system,
the peptide inhibitor is most likely inhibiting a member of the
caspase family with similar substrate speci¢cities, that is one
in Group III. We therefore tested the e¡ects of an inhibitor of
the initiator caspase 8 [20] on sphingolipid induced apoptosis.
The inhibitor Z-IETD-FMK inhibited both Sph and DMS
induced apoptosis by up to 50%, but neither ceramide ana-
logue was inhibited from inducing apoptosis (Fig. 2).
The inhibition of Sph/DMS induced apoptosis by Z-IETD-
FMK was not as dramatic as that seen with the other inhib-
itors, but was linear and signi¢cant at each dose (Fig. 3D).
This most likely represents the kinetics involved in blocking a
FEBS 19965 19-3-98
Fig. 2. E¡ect of caspase inhibitors on sphingolipid induced apopto-
sis in HL60 cells. Cells were preincubated for 1 h with the indicated
inhibitor and treated for 5.5 h with 20 WM Sph or DMS, or 50 WM
C2-ceramide (C2Cer) or C6-ceramide (C6Cer) then analyzed by £ow
cytometry for apoptosis as described in Section 2. Data are of two
or three separate experiments, mean þ S.E.
Fig. 1. E¡ect of lipid enzyme inhibitors on sphingolipid induced apoptosis in HL60 cells. Cells were preincubated for 1 h with (A) 25 WM Fu-
monisin B1 or (B) 10 WM MAPP then treated for 5.5 h with 20 WM Sph or DMS or 50 WM C6-ceramide (C6Cer) then analyzed for apoptosis
by £ow cytometry as described in Section 2. Data are of two or three separate experiments, mean þ S.D.
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single upstream protease in such a cascade rather than multi-
ple enzymes. No inhibition was seen with either ceramide
analog at even the highest concentrations, with some in-
creased apoptosis. These data suggest that Sph/DMS act early
in the apoptosis pathway whereas ceramide functions down-
stream of the early Group III caspases but upstream of those
in Group II.
During receptor-generated apoptosis caspase 8/FLICE
binds to FADD, a death associated molecule considered to
be a common link in receptor-generated apoptosis [23], and
then cleaves itself, initiating a caspase cascade. GraB also acts
as an initiator caspase in the target cell, and is known to share
some substrates with caspase 8, including caspase 8 itself as
well as downstream caspases [2]. Thus, GraB (or some other
Group III caspase) could act in parallel with, or cleave and
activate caspase 8 to initiate the cascade. Other non-caspase
proteases cannot be ruled as having a role in apoptosis, per-
haps similar to that of GraB. Proteases have been shown to
cleave caspase zymogens at alternative sites to give rise to
active forms [2]. It is quite possible that Sph is initiating the
apoptosis pathway through a non-caspase protease not yet
identi¢ed which is able to cleave caspase 8.
Caspase 8 and GraB [24] are both inhibited by the viral
protein CrmA, which shows surprising a⁄nity for caspase 8
but not other death-related caspases [25], but ceramide in-
duced apoptosis is not inhibited by CrmA [26,27]. On the
other hand, the baculovirus protein p35 which inhibits a vari-
ety of caspases including caspase 3, reportedly inhibited ce-
ramide analogue induced apoptosis [26,27]. Additionally, it
has recently been reported that ceramide does not induce ac-
tivation of caspase 8/FLICE, but does activate both caspase 3
and 7 [28]. Together, these studies support our conclusion that
ceramides induce apoptosis downstream from the initiator
phase, but upstream from the execution phase caspases.
The results presented here on the relationship between var-
ious caspase inhibitors and sphingolipid induced apoptosis are
summarized in Table 1. In conclusion, these data strongly
suggest that Sph/DMS act separately from ceramide in the
apoptosis pathway and further imply that Sph/DMS act ear-
lier than ceramide in the apoptotic pathway, upstream from
even the early caspases, whereas the point of action for cer-
amide is downstream of the initiating caspases, but upstream
from the executors.
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